COMPOSITIONS AND METHODS FOR T CELL ENGINEERING

• Main Authors: QIU SHUYI, LIU LIPING, SHI ZHONGDONG, SUN JING, WANG XINXIN, YANG CHUNHUI, CAO WEI, JIN TAO
• Format: Patent
• Language: Chinese; English
• Published: 10.09.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The disclosure relates to an engineered immune cell and use thereof. The engineered immune cell provided in the disclosure comprises a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity. 本公开涉及工程化免疫细胞及其用途。本公开提供了包含CAR或工程化TCR的工程化免疫细胞，该CAR或工程化TCR可包含第一抗原结合结构域和第二抗原结合结构域。当将本公开的工程化免疫细胞施用于受试者时，其可以抑制宿主免疫细胞例如T细胞和/或NK细胞，并增强工程化免疫细胞在体内的存活和持久性，从而表现出更有效的肿瘤杀死活性。